[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517162":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":18,"centralContacts":39,"locations":49,"responsibleParty":67,"collaborators":71,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":18,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":18,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":52,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"eiDBS suppression","EXPERIMENTAL","Closed-loop evoked interference DBS that suppresses beta oscillations.",[13],"Device: Neurostimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Off DBS","NO_INTERVENTION","Off-stimulation and off-medication",null,{"label":20,"type":10,"description":21,"interventionNames":22},"eiDBS amplification","Closed-loop evoked interference DBS that amplifies beta oscillations.",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Levodopa medication","On-medication, off-stimulation",[27],"Drug: Carbidopa 25\u002FLevodopa 100Mg Tab",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":18},"DEVICE","Neurostimulation","Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.",[20,9],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":18},"DRUG","Carbidopa 25\u002FLevodopa 100Mg Tab","Anti-parkinsonian medication.",[24],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":18,"email":44},"David Escobar, PhD","CONTACT","216-390-1907","escobad2@ccf.org",{"name":46,"role":42,"phone":47,"phoneExt":18,"email":48},"Jeffrey Negrey, MA","216-316-6896","negreyj2@ccf.org",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Cleveland Clinic","RECRUITING","Cleveland","Ohio","44195","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-81.69541,41.4995,{"lat":62,"lon":61},[65,66],{"name":41,"role":42,"phone":43,"phoneExt":18,"email":44},{"name":46,"role":42,"phone":47,"phoneExt":18,"email":48},{"type":68,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","David Escobar","Assistant Staff",[72],{"name":5,"class":6},"100517162","phase-4-personalized-real-time-dbs-and-pd-mechanisms-100517162",false,"NCT06013956","Personalized Real-Time DBS and PD Mechanisms","Identifying Circuit Dynamics Underlying Motor Dysfunction in Parkinson's Disease Using Real-Time Neural Control","Key Inclusion Criteria:\n\n* Ability to provide informed consent.\n* Clinical diagnosis of idiopathic Parkinson's disease.\n* Determined, as per standard of care, to be a candidate for deep brain stimulation (DBS) surgery targeting the subthalamic nucleus.\n* Ability to tolerate delays in taking daily standard Parkinson's disease medications.\n\nKey Exclusion Criteria:\n\n* Secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's disease.\n* Patient has a condition that, in the opinion of the investigators, would significantly increase the risk of interfering with study compliance, safety, or outcome.","ALL","18 Years","80 Years",{"count":84,"type":85},25,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling. The ultimate goal of this study is to inform the development of closed-loop neuromodulation technology that can be programmed and adjusted in real time based on patient-specific neural activity.",[91],"Parkinson Disease",[93],"Deep Brain Stimulation","2026-08-19",{"date":96,"type":97},"2026-08-20","ACTUAL",{"date":99,"type":97},"2023-08-29",{"date":101,"type":85},"2028-06-30",{"name":69,"class":6},1]